No licensed hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, despite recent Andes virus outbreaks with confirmed cases and person-to-person transmission potential. Early-stage candidates, including DNA and mRNA platforms from preclinical studies and limited Phase 1 trials, have shown immunogenicity in animal models and small human cohorts, but no Phase 3 efficacy trials are underway. Vaccine development timelines, regulatory requirements for safety data on rare rodent-borne pathogens, and the absence of large-scale field testing amid low baseline incidence keep market-implied odds for approval this year near zero. Unexpected emergency authorization or accelerated regulatory pathways could shift consensus if new outbreak data emerge, though current surveillance from CDC and WHO shows limited risk.